![](http://glenmarkpharma.com/wp-content/uploads/slider/cache/deb8528034602ab74ae695d909b83bd3/lady.jpg)
![](http://glenmarkpharma.com/wp-content/uploads/slider/cache/6c25578acbcca678bc0304199033dafa/DISCOVERING-ADVANCE-THERAPIES-FOR-A-NEW-WORLD.jpg)
![](http://glenmarkpharma.com/wp-content/uploads/slider/cache/e9c40c974d00dc30c98e9e78341b78c1/A-NEW-WORLD-A-HEALTHIER-WORLD.jpg)
![](http://glenmarkpharma.com/wp-content/uploads/slider/cache/f6a611ed82b5ec1c593637874300fc6b/banner6.jpg)
Banner 2
A NEW WAY FOR A NEW WORLD
At Glenmark, we believe in enriching lives and making a difference to patients all over the world. We constantly strive to find new ways that pave the way for a healthier tomorrow.
Banner 3
DISCOVERING ADVANCE THERAPIES FOR A NEW WORLD
We are creating centers of excellence in dermatology, oncology and respiratory therapy. The effort is to develop advance therapies to enrich the lives of patients worldwide.
Banner 4
A NEW WORLD.
A HEALTHIER WORLD.
A HEALTHIER WORLD.
With 14 manufacturing facilities in four countries and 4 R&D centres spanning across GPL and GLS, we work relentlessly towards improving the quality of life of patients across the globe.
Banner 5
A NEW WAY FOR A NEW WORLD BEGINS WITH US
Employees based out of 50+ offices all over the world working towards one mission - Enriching lives globally.
INVESTOR CORNER
ANNOUNCEMENTS
- Glenmark Pharma reports consolidated revenue growth of 6.9%, EBITDA margin of 18.1%, and PAT margin of 10.5% YoY for Q1 FY 2024-25
-
Board Meeting Intimation –
14 August 2024 - Glenmark Pharma MDA Q4 FY2023-24
- Glenmark Pharma Reports Q4 FY2023-24 Financial results
- Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India
![invest_corn_home](https://Glenmark.b-cdn.net/wp-content/uploads/2024/03/invest_corn_home.jpg)